Get App Open
In App
Open App
you are here:

Eris Lifesciences Ltd.

BSE: 540596 | NSE: ERIS |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE406M01024 | SECTOR: Pharmaceuticals & Drugs

BSE Live

Dec 02, 16:01
665.00 -5.25 (-0.78%)
Volume
AVERAGE VOLUME
5-Day
5,018
10-Day
3,839
30-Day
7,090
3,529
  • Prev. Close

    670.25

  • Open Price

    670.95

  • Bid Price (Qty.)

    663.00 (41)

  • Offer Price (Qty.)

    669.00 (30)

NSE Live

Dec 02, 15:41
664.85 -5.10 (-0.76%)
Volume
AVERAGE VOLUME
5-Day
35,296
10-Day
27,982
30-Day
39,683
21,420
  • Prev. Close

    669.95

  • Open Price

    676.65

  • Bid Price (Qty.)

    664.85 (30)

  • Offer Price (Qty.)

    0.00 (0)

ANNOUNCEMENTS ON Eris Life

  • Nov 09, 2022 10:54 Source: BSE

    Eris Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING

  • Nov 07, 2022 17:08 Source: BSE

    Eris Lifesciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    INTIMATION OF SCHEDULE OF ANALYST / INSTITUTIONAL INVESTOR MEETING

  • Oct 31, 2022 18:48 Source: BSE

    Eris Lifesciences - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    TRANSCRIPT OF ANALYST AND INVESTOR CALL

  • Oct 20, 2022 13:01 Source: BSE

    Eris Lifesciences - Announcement under Regulation 30 (LODR)-Investor Presentation

    Pursuant to the requirement of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached the investor presentation made by the Company.

  • Oct 20, 2022 12:49 Source: BSE

    Eris Lifesciences - Board Meeting Outcome for OUTCOME OF THE BOARD MEETING

    We hereby inform that the Board of Directors of the Company at their meeting held today i.e. 20 October 2022 has, inter alia, transacted the following business: ? Approved and took on record the limited reviewed Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September 2022. The duly signed Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September 2022 are enclosed herewith. ? The Board considered the re-classification request received from M/s. Shah & Co. The Board reviewed the application received and formed a view that the said request does not prejudice the interests of the Company and its stakeholders in any manner. The Board, therefore, approved the proposal and approved its reference to the stock exchanges for their approval in terms of Regulation 31A of Listing Regulations. The meeting of the Board of Directors commenced at 11:00 A.M. and concluded at 12:30 P.M.

  • Oct 20, 2022 12:43 Source: BSE

    Eris Lifesciences - Results-Financial Results For The Quarter And Half Year Ended 30Th September, 2022

    We hereby inform that the Board of Directors of the Company at their meeting held today i.e. 20 October 2022 has, inter alia, transacted the following business:? Approved and took on record the limited reviewed Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September 2022.The duly signed Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended 30th September 2022 are enclosed herewith.? The Board considered the re-classification request received from M/s. Shah & Co. The Board reviewed the application received and formed a view that the said request does not prejudice the interests of the Company and its stakeholders in any manner. The Board, therefore, approved the proposal and approved its reference to the stock exchanges for their approval in terms of Regulation 31A of Listing Regulations.

CORPORATE ANNOUNCEMENTS

BOARD MEETING

Meeting Date : Oct 20, 2022
Remark : Quarterly Results